CDKN2A and neoplasm: OncoKB actionable alterations recapitulated in our cohort revealed 3 potential targets (Figure 5B), including CDKN2A, FLG, and ERBB2. Two patients harbored a CDKN2A mutation/deletion, which had compelling biological evidence (Level 4) with a predicted response to drugs in all tumor types.